Coda’s chemogenetics convinces investors to re-up in series A extension

Cellular data for Coda’s chemogenetic therapy convinced its existing investors to back a $15 million extension of the company’s series A round, which will enable the biotech to generate in vivo data and choose clinical candidates for neuropathic pain and focal epilepsy.

The extension, which was led by Versant Ventures, brings the round’s total to $34 million. Fellow existing investors MPM Capital and Astellas Venture Management also participated. ...